Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging
FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating 68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate cancer setting. The designation recognizes the program's potential to address an important unmet need...